Literature DB >> 26191365

Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor.

Alexei S Karpov1, Payman Amiri2, Cornelia Bellamacina2, Marie-Helene Bellance1, Werner Breitenstein1, Dylan Daniel2, Regis Denay1, Doriano Fabbro1, Cesar Fernandez1, Inga Galuba1, Stephanie Guerro-Lagasse1, Sascha Gutmann1, Linda Hinh2, Wolfgang Jahnke1, Julia Klopp1, Albert Lai2, Mika K Lindvall2, Sylvia Ma2, Henrik Möbitz1, Sabina Pecchi2, Gabriele Rummel1, Kevin Shoemaker2, Joerg Trappe1, Charles Voliva2, Sandra W Cowan-Jacob1, Andreas L Marzinzik1.   

Abstract

The discovery of inhibitors targeting novel allosteric kinase sites is very challenging. Such compounds, however, once identified could offer exquisite levels of selectivity across the kinome. Herein we report our structure-based optimization strategy of a dibenzodiazepine hit 1, discovered in a fragment-based screen, yielding highly potent and selective inhibitors of PAK1 such as 2 and 3. Compound 2 was cocrystallized with PAK1 to confirm binding to an allosteric site and to reveal novel key interactions. Compound 3 modulated PAK1 at the cellular level and due to its selectivity enabled valuable research to interrogate biological functions of the PAK1 kinase.

Entities:  

Keywords:  PAK1; allosteric inhibitor; dibenzodiazepine; p21 activated kinase; tool compound

Year:  2015        PMID: 26191365      PMCID: PMC4499825          DOI: 10.1021/acsmedchemlett.5b00102

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  27 in total

Review 1.  Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitations.

Authors:  Jeyanthy Eswaran; Da-Qiang Li; Anil Shah; Rakesh Kumar
Journal:  Clin Cancer Res       Date:  2012-05-17       Impact factor: 12.531

2.  An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.

Authors:  Sean W Deacon; Alexander Beeser; Jami A Fukui; Ulrike E E Rennefahrt; Cynthia Myers; Jonathan Chernoff; Jeffrey R Peterson
Journal:  Chem Biol       Date:  2008-04

3.  Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth.

Authors:  Brion W Murray; Chuangxing Guo; Joseph Piraino; John K Westwick; Cathy Zhang; Jane Lamerdin; Eleanor Dagostino; Daniel Knighton; Cho-Ming Loi; Michael Zager; Eugenia Kraynov; Ian Popoff; James G Christensen; Ricardo Martinez; Susan E Kephart; Joseph Marakovits; Shannon Karlicek; Simon Bergqvist; Tod Smeal
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

4.  Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases.

Authors:  Sandra W Cowan-Jacob; Wolfgang Jahnke; Stefan Knapp
Journal:  Future Med Chem       Date:  2014-04       Impact factor: 3.808

5.  Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition.

Authors:  Wen-I Wu; Walter C Voegtli; Hillary L Sturgis; Faith P Dizon; Guy P A Vigers; Barbara J Brandhuber
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

6.  Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.

Authors:  Le Wang; Gerard M Sullivan; Laura A Hexamer; Lisa A Hasvold; Reema Thalji; Magdalena Przytulinska; Zhi-Fu Tao; Gaoquan Li; Zehan Chen; Zhan Xiao; Wen-Zhen Gu; John Xue; Mai-Ha Bui; Philip Merta; Peter Kovar; Jennifer J Bouska; Haiying Zhang; Chang Park; Kent D Stewart; Hing L Sham; Thomas J Sowin; Saul H Rosenberg; Nan-Horng Lin
Journal:  J Med Chem       Date:  2007-07-21       Impact factor: 7.446

7.  Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486.

Authors:  Bridget M Dolan; Sergio G Duron; David A Campbell; Benedikt Vollrath; B S Shankaranarayana Rao; Hui-Yeon Ko; Gregory G Lin; Arvind Govindarajan; Se-Young Choi; Susumu Tonegawa
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-18       Impact factor: 11.205

8.  PAK signaling in cancer.

Authors:  Diana Zi Ye; Jeffrey Field
Journal:  Cell Logist       Date:  2012-04-01

9.  Recent advances in the development of p21-activated kinase inhibitors.

Authors:  Natalia Coleman; Joseph Kissil
Journal:  Cell Logist       Date:  2012-04-01

Review 10.  p21-activated kinase 1: PAK'ed with potential.

Authors:  Christy C Ong; Adrian M Jubb; Wei Zhou; Peter M Haverty; Adrian L Harris; Marcia Belvin; Lori S Friedman; Hartmut Koeppen; Klaus P Hoeflich
Journal:  Oncotarget       Date:  2011-06
View more
  23 in total

1.  Neuroprotective Effects of 2-Substituted 1, 3-Selenazole Amide Derivatives on Amyloid-Beta-Induced Toxicity in a Transgenic Caenorhabditis Elegans Model of Alzheimer's Disease.

Authors:  Huiying Wang; Yuandong Yue; Haifeng Zhao; Hao Wu; Kai Jiang; Shuang Li; Meihua Zhao; Feng Lin
Journal:  Neurotox Res       Date:  2021-01-05       Impact factor: 3.911

2.  Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors.

Authors:  Dries J H De Clercq; David E Heppner; Ciric To; Jaebong Jang; Eunyoung Park; Cai-Hong Yun; Mierzhati Mushajiang; Bo Hee Shin; Thomas W Gero; David A Scott; Pasi A Jänne; Michael J Eck; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2019-10-22       Impact factor: 4.345

3.  Identifying three-dimensional structures of autophosphorylation complexes in crystals of protein kinases.

Authors:  Qifang Xu; Kimberly L Malecka; Lauren Fink; E Joseph Jordan; Erin Duffy; Samuel Kolander; Jeffrey R Peterson; Roland L Dunbrack
Journal:  Sci Signal       Date:  2015-12-01       Impact factor: 8.192

Review 4.  Targeting PAK1.

Authors:  Galina Semenova; Jonathan Chernoff
Journal:  Biochem Soc Trans       Date:  2017-02-08       Impact factor: 5.407

Review 5.  Group I PAKs in myelin formation and repair of the central nervous system: what, when, and how.

Authors:  Yan Wang; Fuzheng Guo
Journal:  Biol Rev Camb Philos Soc       Date:  2021-11-22

6.  PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling.

Authors:  Arti Verma; Sandeep Artham; Abdulrahman Alwhaibi; Mir S Adil; Brian S Cummings; Payaningal R Somanath
Journal:  Biochem Pharmacol       Date:  2020-03-30       Impact factor: 5.858

7.  The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin.

Authors:  Tatiana Y Prudnikova; Jonathan Chernoff
Journal:  Small GTPases       Date:  2016-07-18

8.  PAK1 Positively Regulates Oligodendrocyte Morphology and Myelination.

Authors:  Tanya L Brown; Hirokazu Hashimoto; Lisbet T Finseth; Teresa L Wood; Wendy B Macklin
Journal:  J Neurosci       Date:  2021-01-21       Impact factor: 6.709

Review 9.  Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates.

Authors:  Xing-Hua Xiao; Lin-Chen Lv; Jing Duan; Ye-Meng Wu; Shu-Jin He; Zhen-Zhen Hu; Li-Xia Xiong
Journal:  Molecules       Date:  2018-03-29       Impact factor: 4.411

Review 10.  Trends in kinase drug discovery: targets, indications and inhibitor design.

Authors:  Misty M Attwood; Doriano Fabbro; Aleksandr V Sokolov; Stefan Knapp; Helgi B Schiöth
Journal:  Nat Rev Drug Discov       Date:  2021-08-05       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.